ArticleTranslational lung cancer research2026
Utilizing clinical features, genetic mutations, and a 14-gene molecular assay for optimizing the management of multiple primary lung cancer.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The increasing detection of multiple primary lung cancers (MPLCs) has outpaced the development of corresponding evidence-based management strategies. Current clinical practice remains constrained by two major limitations: (I) imperfect distinction between MPLC and intrapulmonary metastasis (IM) using imaging and pathology alone; and (II) the absence of standardized, lesion-level postoperative risk tools to guide adjuvant therapy and surveillance. To further optimize MPLC clinical management, we applied a 14-gene RNA-level molecular assay to examine its association with clinical factors and its potential to optimize clinical decision-making. Methods: A total of 69 nodules from 30 patients were prospectively included for analysis. Patient demographic information, nodule characteristics, imaging features, histopathological characteristics, and mutation profiles obtained by next-generation sequencing (NGS) were collected for analysis. Additionally, all nodules were prospectively assessed for risk scores and stratifications with a 14-gene molecular assay. We performed correlation analyses between nodule-level risk stratification and the aforementioned clinical variables to evaluate the relationship between the 14-gene molecular assay-based risk assessment and conventional clinical factors. Results: We found that the majority of patients with MPLC were female and had a high frequency of a family history of cancer. Higher maximum diameter, computed tomography (CT) value, maximum standardized uptake value (SUVmax), and solid component on imaging were associated with greater invasiveness. Less invasive MPLC lesions more frequently harbored Conclusions: The 14-gene RNA expression assay may help prioritize high-risk lesions requiring clinical intervention, and provide guidance for postoperative adjuvant therapy and surveillance strategies, thereby optimizing treatment for MPLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.